News

Page:
  • 1

Gyroscope Therapeutics announces first patient dosed in Phase I/II FOCUS study in dry AMD

19th February 2019 by Sarah Neale

 Stevenage, 19 February 2019 – Gyroscope Therapeutics (Gyroscope), an ophthalmology company developing genetically defined therapies for retinal diseases, has commenced dosing in a Phase I/II clinical trial in dry age-related macular degeneration (AMD). The FOCUS...